---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-054475"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:43:05.815853+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Treace Medical Q1 revenue $51.1M (+21% YoY), cuts FY2024 guidance to $201-$211M

## Summary
- Q1 revenue $51.1M (+21% YoY); net loss $18.7M ($0.30/share) vs $13.5M loss in Q1 2023.
- FY2024 revenue guidance slashed to $201-$211M from $220-$225M, citing increased MIS Osteotomy competition and knockoffs.
- Adjusted EBITDA loss improved to $8.3M in Q1 from $10.0M in prior year.
- CEO plans two new 3D MIS Osteotomy launches later in 2024 to counter competitive headwinds.
- Cash and marketable securities $112.1M; 63 granted US patents as of March 31, 2024.

## SEC filing metadata
- accession: 0000950170-24-054475
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017024054475/0000950170-24-054475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017024054475/tmci-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-054475
- JSON: https://secwatch.observer/filing/0000950170-24-054475.json
- Plain text: https://secwatch.observer/filing/0000950170-24-054475.txt

## Key facts
- Earnings Releases
  TREACE MEDICAL CONCEPTS, INC. reported the first quarter ended March 31, 2024 results: revenue $51.1 million, net income ($18.7) million, EPS ($0.30) per share. Guidance lowered.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $51.1 million
  - Net income: ($18.7) million
  - EPS: ($0.30) per share
  - Guidance: lowered
  - Result: reported results
  source text: through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Revenue of $51.1 million in first quarter 2024 increased 21% over same period in 2023 • Gross margin of 80.2% in first quarter 2024 • First quarter 2024 net loss attributable to common stockholders was
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630627/000095017024054475/0000950170-24-054475-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.